After the establishment of the National Center for Disease Control and Prevention, many foreign vaccine companies have adjusted their Chinese teams

The new crown epidemic not only changes the way of life of every Chinese, but also changes the development of the domestic vaccine industry
.

The Health Knowledge Bureau recently learned that the Pfizer vaccine team has started layoffs, and the compensation policy is N+2+1
.

Almost at the same time, Sanofi's vaccine business announced a restructuring, specifically merging multiple teams such as key customers and hospital customers with the business promotion team

Pfizer's vaccine team has started layoffs, and the compensation policy is N+2+1

A person who has been in the vaccine business for a long time told the Health Knowledge Bureau that the epidemic has promoted the public's awareness of vaccine products, and the continuous investment in research and development by domestic manufacturers has forced multinational pharmaceutical companies to cope with the adjustment of "localization substitution" in the Chinese market
.

Make multinational pharmaceutical companies have to deal with the adjustment of "localization substitution" in the Chinese market

In February of this year, the National Center for Disease Control and Prevention's "Three Plans" was released, which for the first time clarified the functional configuration, internal institutions and staffing of the National Centers for Disease Control and Prevention.
Legalization of Liability
.

This "three set plan" is clear: the CDC should not only formulate a national immunization plan, but its Health and Immunization Planning Department should also organize the construction of a vaccination service system and information system , and organize vaccines for the immunization effect of infectious disease prevention and control.
assessment
.

The Department of Health and Immunization Planning will also organize the construction of vaccination service system and information system.

With the rapid rise of many domestic companies such as Watson Bio, Wantai Bio, CanSino, and Sinopharm Group, the technology of vaccine products has gradually caught up with multinational pharmaceutical companies, and the national support policy will gradually be inclined in the future
.

The industry generally believes that the localization of China's vaccine market will accelerate in the future , and the second- class vaccine market is expected to expand in a new round

In the future, the national support policy will gradually tilt , and the localization of China's vaccine market will accelerate in the future

The "Three Plans" are introduced, and the CDC strengthens the right to speak

The "Three Plans" are introduced, and the CDC strengthens the right to speak

Looking at the global vaccine market, it is still in an oligopolistic market situation.
The four giants, Sanofi, GlaxoSmithKline, Merck, and Pfizer, account for almost 80% of the market share
.

In China, it also has the right to speak in the market with a variety of blockbuster varieties

However, the arrival of the new crown epidemic has completely reversed the long-term backwardness of domestic brands
.

However, the arrival of the new crown epidemic has completely reversed the long-term backwardness of domestic brands
.

In January 2020, the spread of the new coronavirus appeared in Wuhan and other cities in China
.

The State Council immediately established a joint prevention and control mechanism group, and established a strategy of advancing five technical routes of inactivated vaccines, nucleic acid vaccines, attenuated influenza virus vector vaccines, adenovirus vector vaccines and recombinant protein vaccines

Five technical routes for inactivated vaccines, nucleic acid vaccines, attenuated influenza virus vector vaccines, adenovirus vector vaccines and recombinant protein vaccines

Beijing Bio, Kexing Zhongwei, Taikang Bio, CanSino and other domestic pharmaceutical companies have stepped up research and development, and have approved the new crown vaccine in the shortest possible time
.

Analysts pointed out that although there are practical difficulties in the research and development of the new crown vaccine, after the breakthrough, the research and development level of domestic pharmaceutical companies has reached a new level

After the breakthrough, the research and development level of domestic pharmaceutical companies has reached a new level

In the past, the Chinese public was not familiar with the product development, clinical use and precautions of vaccines.
The new crown epidemic is undoubtedly an excellent opportunity to increase public awareness, strengthen corporate research and development capabilities, and improve the government's regulatory system
.

The introduction of the National Centers for Disease Control and Prevention's "Three Decisions Plan" is the first time to determine the independent status of the national disease control department, upgrade the administrative level, and increase the establishment.
This is also a strong support for the lack of voice of the disease control department in the past
.

This is also a strong support for the lack of voice of the disease control department in the past

The Health Knowledge Bureau noticed that after the establishment of the National Centers for Disease Control and Prevention, the Prevention and Control Bureau and the Comprehensive Supervision Bureau of the National Health Commission will be revoked, and some disease prevention functions that were originally scattered in the two internal agencies will be unified under the National Centers for Disease Control and Prevention.
, the health supervision function returns to the disease control system
.

From the perspective of division of powers, the newly established National Centers for Disease Control and Prevention is more focused on the prevention and control of infectious diseases, planning for epidemic monitoring, in charge of responding to infectious diseases, and coordinating disease prevention and control.
The prevention and control management is still under the supervision of the National Health Commission
.

A top-down regulatory reform has kicked off, and China's vaccine industry will also undergo fundamental changes
.

China's vaccine industry will also undergo fundamental changes

Vaccines accelerate the "localization" of China's vaccine market logic changes

Vaccines accelerate the "localization" of China's vaccine market logic changes

Even without the impact of the epidemic, after the accelerated pace of localization and substitution, the vaccine business of multinational pharmaceutical companies has not been easy in recent years
.

This is the case with the once most popular vaccine "Peier".
"Peier" is a 13-valent pneumococcal conjugate vaccine developed by Pfizer and has been among the top 10 best-selling drugs in the world for many times
.

In 2018, global sales of the vaccine reached $5.

In China, Pfizer's "Peier" was blocked by domestic similar products
.

In China, Pfizer's "Peier" was blocked by domestic similar products
.

At the end of 2020, Watson Bio's domestic 13-valent pneumonia conjugate vaccine (trade name "Woanxin") was approved for marketing, breaking Pfizer's long-term monopoly on this variety
.

According to the financial report of Watson Bio, the batch issuance of "Peier" in 2020 was 6.

"Peier" is currently Pfizer's best-selling vaccine variety in the Chinese market.
Unexpectedly, in the first year of the launch of domestic varieties, it will be able to "wrestle arms " with multinational pharmaceutical companies
.

Unexpectedly, in the first year of listing of domestic varieties, they will be able to "wrestle arms" with multinational pharmaceutical companies

Watson's performance forecast for 2021 shows that the sales revenue of "Wo Anxin" increased by about 66% compared with the same period of the previous year
.
In contrast, Pfizer's market performance has been reported since the end of last year, such as "lowering performance appraisal indicators" and "outsourcing of business pilots"
.
Analysts pointed out that the 13-valent pneumonia vaccine has now formed the resistance of domestic imitation and imported original research chambers
.

The 13-valent pneumonia vaccine is only a microcosm of domestic vaccine development
.
Based on the value of the vaccine batches issued in 2020, the nine-valent HPV vaccine, the quadrivalent HPV vaccine, and the quadrivalent influenza virus split vaccine were shortlisted
.
Among these vaccines, some are already the leading role in domestic production, and some will soon usher in the impact of domestic varieties
.

Among these vaccines, some are already the leading role in domestic production, and some will soon usher in the impact of domestic varieties
.

In June 2018, the State Food and Drug Administration approved the listing applications of Hualan Bio and Changsheng Bio for the quadrivalent influenza vaccine, and Wantai Canghai's domestic bivalent HPV vaccine was approved for marketing in December 2019
.
The live attenuated varicella vaccine, Sabin strain polio inactivated vaccine, freeze-dried human rabies vaccine, 23-valent pneumococcal polysaccharide vaccine and other products have all achieved "localization"
.

Even the most popular 9-valent HPV vaccine in recent years is expected to usher in domestic products soon .
Therefore, Merck proposed to "increase the supply of 9-valent HPV vaccine in the Chinese market" this year, trying to increase the supply of 9-valent HPV vaccines in the Chinese market.
to seize the market
.

Even the most popular 9-valent HPV vaccine in recent years is expected to usher in domestic products soon

With the influence of factors such as an aging population and the opening of the two-child policy, China's vaccine industry has a huge market space
.
However, giants such as Pfizer, Merck, Sanofi, and GlaxoSmithKline will face the impact of domestic companies
.
With the emergence of the National Center for Disease Control and Prevention, it will undoubtedly change the existing market structure
.